Can acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors be overcome by different small-molecule tyrosine kinase inhibitors?

被引：5

作者：

Bunn, Paul A., Jr. ^{[1
]}

机构：

[1] Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA

[2] Univ Colorado, Ctr Canc, Denver, CO 80262 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期

关键词：

D O I：

10.1200/JCO.2007.11.3258

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2504 / 2505

页数：2

共 21 条

[1]

ALBERTI W, 1995, BRIT MED J, V311, P899

[2] A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations [J].

Asahina, H. ;

Yamazaki, K. ;

Kinoshita, I. ;

Sukoh, N. ;

Harada, M. ;

Yokouchi, H. ;

Ishida, T. ;

Ogura, S. ;

Kojima, T. ;

Okamoto, Y. ;

Fujita, Y. ;

Dosaka-Akita, H. ;

Isobe, H. ;

Nishimura, M. .

BRITISH JOURNAL OF CANCER, 2006, 95 (08) :998-1004

[3] Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib [J].

Cho, Byoung Chul ;

Im, Chong-Kun ;

Park, Moo-Suk ;

Kim, Se Kyu ;

Chang, Joon ;

Park, Jong Pil ;

Choi, Hye Jin ;

Kim, Yu Jin ;

Shin, Sang-Joon ;

Sohn, Joo Hyuk ;

Kim, Hoguen ;

Kim, Joo Hang .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18) :2528-2533

[4] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].

Fukuoka, M ;

Yano, S ;

Giaccone, G ;

Tamura, T ;

Nakagawa, K ;

Douillard, JY ;

Nishiwaki, Y ;

Vansteenkiste, J ;

Kudoh, S ;

Rischin, D ;

Eek, R ;

Horai, T ;

Noda, K ;

Takata, I ;

Smit, E ;

Averbuch, S ;

Macleod, A ;

Feyereislova, A ;

Dong, RP ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246

[5] Case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma [J].

Garfield, DH .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) :7738-7740

[6] Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT1 [J].

Giaccone, G ;

Herbst, RS ;

Manegold, C ;

Scagliotti, G ;

Rosell, R ;

Miller, V ;

Natale, RB ;

Schiller, JH ;

von Pawel, J ;

Pluzanska, A ;

Gatzemeier, M ;

Grous, J ;

Ochs, JS ;

Averbuch, SD ;

Wolf, MK ;

Rennie, P ;

Fandi, A ;

Johnson, DH .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :777-784

[7] Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer [J].

Hanna, Nasser ;

Lilenbaum, Rogerio ;

Ansari, Rafat ;

Lynch, Thomas ;

Govindan, Ramaswamy ;

Jaenne, Pasi A. ;

Bonomi, Philip .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (33) :5253-5258

[8] TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer [J].

Herbst, RS ;

Prager, D ;

Hermann, R ;

Fehrenbacher, L ;

Johnson, BE ;

Sandler, A ;

Kris, MG ;

Tran, HT ;

Klein, P ;

Li, X ;

Ramies, D ;

Johnson, DH ;

Miller, VA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5892-5899

[9] Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer [J].

Hirsch, Fred R. ;

Varella-Garcia, Marileila ;

Bunn, Paul A., Jr. ;

Franklin, Wilbur A. ;

Dziadziuszko, Rafal ;

Thatcher, Nick ;

Chang, Alex ;

Parikh, Purvish ;

Rodrigues Pereira, Jose ;

Ciuleanu, Tudor ;

von Pawel, Joachim ;

Watkins, Claire ;

Flannery, Angela ;

Ellison, Gillian ;

Donald, Emma ;

Knight, Lucy ;

Parums, Dinah ;

Botwood, Nicholas ;

Holloway, Brian .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (31) :5034-5042

[10] An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor [J].

Kobayashi, S ;

Ji, HB ;

Yuza, Y ;

Meyerson, M ;

Wong, KK ;

Tenen, DG ;

Halmos, B .

CANCER RESEARCH, 2005, 65 (16) :7096-7101

← 1 2 3 →